397 related articles for article (PubMed ID: 31256135)
1. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.
Bomba M; Granzotto A; Castelli V; Onofrj M; Lattanzio R; Cimini A; Sensi SL
J Alzheimers Dis; 2019; 70(3):793-810. PubMed ID: 31256135
[TBL] [Abstract][Full Text] [Related]
2. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice.
Bomba M; Granzotto A; Castelli V; Massetti N; Silvestri E; Canzoniero LMT; Cimini A; Sensi SL
Neurobiol Aging; 2018 Apr; 64():33-43. PubMed ID: 29331730
[TBL] [Abstract][Full Text] [Related]
3. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
Bomba M; Ciavardelli D; Silvestri E; Canzoniero LM; Lattanzio R; Chiappini P; Piantelli M; Di Ilio C; Consoli A; Sensi SL
Cell Death Dis; 2013 May; 4(5):e612. PubMed ID: 23640454
[TBL] [Abstract][Full Text] [Related]
4. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Abdelwahed OM; Tork OM; Gamal El Din MM; Rashed L; Zickri M
Brain Res Bull; 2018 May; 139():67-80. PubMed ID: 29421245
[TBL] [Abstract][Full Text] [Related]
6. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
7. Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.
An J; Zhou Y; Zhang M; Xie Y; Ke S; Liu L; Pan X; Chen Z
Behav Brain Res; 2019 Sep; 370():111932. PubMed ID: 31082410
[TBL] [Abstract][Full Text] [Related]
8. Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.
King MR; Anderson NJ; Deciu M; Guernsey LS; Cundiff M; Hajizadeh S; Jolivalt CG
J Neurosci Res; 2020 Nov; 98(11):2357-2369. PubMed ID: 32737929
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease.
Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T
Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165
[TBL] [Abstract][Full Text] [Related]
10. Chenodeoxycholic Acid Ameliorates AlCl
Bazzari FH; Abdallah DM; El-Abhar HS
Molecules; 2019 May; 24(10):. PubMed ID: 31137621
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.
Zhou Y; Li Z; Cao X; Ma H; White PF; Xu X; Jiang Y; Sun X; Cui Y
Brain Res; 2019 Mar; 1706():116-124. PubMed ID: 30408479
[TBL] [Abstract][Full Text] [Related]
12. Exercise Attenuates High-Fat Diet-induced Disease Progression in 3xTg-AD Mice.
Kim D; Cho J; Lee I; Jin Y; Kang H
Med Sci Sports Exerc; 2017 Apr; 49(4):676-686. PubMed ID: 27875496
[TBL] [Abstract][Full Text] [Related]
13. Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons.
Takach O; Gill TB; Silverman MA
Neurobiol Aging; 2015 Mar; 36(3):1378-82. PubMed ID: 25543463
[TBL] [Abstract][Full Text] [Related]
14. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.
Kang X; Wang D; Zhang L; Huang T; Liu S; Feng X; Guo Y; Zhang Z; Wang Z; Ren H; Yuan G
Mol Med; 2023 Sep; 29(1):118. PubMed ID: 37667187
[TBL] [Abstract][Full Text] [Related]
16. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
Batista AF; Forny-Germano L; Clarke JR; Lyra E Silva NM; Brito-Moreira J; Boehnke SE; Winterborn A; Coe BC; Lablans A; Vital JF; Marques SA; Martinez AM; Gralle M; Holscher C; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
J Pathol; 2018 May; 245(1):85-100. PubMed ID: 29435980
[TBL] [Abstract][Full Text] [Related]
17. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.
Li T; Jiao JJ; Hölscher C; Wu MN; Zhang J; Tong JQ; Dong XF; Qu XS; Cao Y; Cai HY; Su Q; Qi JS
Hippocampus; 2018 May; 28(5):358-372. PubMed ID: 29473979
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice.
Sharma S; Taliyan R
Biochem Biophys Res Commun; 2014 Oct; 452(4):1009-15. PubMed ID: 25234596
[TBL] [Abstract][Full Text] [Related]
19. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
Tramutola A; Arena A; Cini C; Butterfield DA; Barone E
Expert Rev Neurother; 2017 Jan; 17(1):59-75. PubMed ID: 27715341
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
